These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11025627)

  • 1. P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs.
    Prabhakar S; Syal P; Srivastava T
    Neurol India; 2000 Sep; 48(3):239-42. PubMed ID: 11025627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease.
    Lukhanina EP; Kapustina MT; Berezetskaya NM; Karaban IN
    Clin Neurophysiol; 2009 Oct; 120(10):1852-8. PubMed ID: 19767236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Auditory event-related potentials in Parkinson's disease: prominent correlation with attention.
    Matsui H; Nishinaka K; Oda M; Kubori T; Udaka F
    Parkinsonism Relat Disord; 2007 Oct; 13(7):394-8. PubMed ID: 17329143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P300 event-related potentials in de novo Parkinson's disease.
    Graham JS; Yiannikas C; Gordon E; Coyle S; Morris JG
    Clin Exp Neurol; 1990; 27():89-98. PubMed ID: 2129963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Event-related potentials in Parkinson's disease.
    Aotsuka A; Weate SJ; Drake ME; Paulson GW
    Electromyogr Clin Neurophysiol; 1996 Jun; 36(4):215-20. PubMed ID: 8803493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The auditory system involvement in Parkinson disease: electrophysiological and neuropsychological correlations.
    Nojszewska M; Pilczuk B; Zakrzewska-Pniewska B; Rowińska-Marcińska K
    J Clin Neurophysiol; 2009 Dec; 26(6):430-7. PubMed ID: 19952569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Parkinson disease and cognitive evoked potentials].
    Gil R; Neau JP; Toullat G; Rivasseau-Jonveaux T; Lefèvre JP
    Rev Neurol (Paris); 1989; 145(3):201-7. PubMed ID: 2749097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
    Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
    Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Auditory event-related potentials in Parkinson's disease.
    Raudino F; Garavaglia P; Beretta S; Pellegrini G
    Electromyogr Clin Neurophysiol; 1997 Oct; 37(7):409-13. PubMed ID: 9402429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [P300 and Parkinson disease. The role of cognitive changes].
    Sartucci F; Guerrini V; Tognoni G; Massetani R; Murri L; Muratorio A
    Riv Neurol; 1990; 60(6):229-33. PubMed ID: 2100048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Event-related potentials, reaction time, and cognitive state in patients with Parkinson's disease.
    Hayashi R; Hanyu N; Shindo M; Tamaru F; Yanagisawa N
    Adv Neurol; 1993; 60():429-33. PubMed ID: 8420167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modality-specific changes in P300 parameters in patients with dementia of the Alzheimer type.
    Pokryszko-Dragan A; Słotwiński K; Podemski R
    Med Sci Monit; 2003 Apr; 9(4):CR130-4. PubMed ID: 12709671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.